Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg initiates coverage of W7 owner Warpaint at 'buy'

(Sharecast News) - Berenberg initiated coverage of Warpaint on Thursday with a 'buy' rating and 550p price target as it said the company's highly cash-generative business model and debt-free balance sheet support strong top-line growth. Warpaint owns the W7 and Technic cosmetics brands. Berenberg noted that its products are among the most affordable in their categories and are distributed across major retail outlets with significant store estates.

"Historically, the business has experienced some challenging periods of end-market performance, linked to the struggling UK high street," it said.

"However, it now has a more diversified and strengthened approach, delivering capital appreciation and persistent end-market outperformance. We expect this to continue given an array of structural and company-specific opportunities ahead."

The bank highlighted a significant margin recovery, noting the gross margin has expanded by 800 basis points since FY 2020, which it perceives as sustainable.

"Historical margin expansion has been driven by growth in end-market volume, coupled with management's strategic decision to refine its non-branded sales focus and acquire its US sales and marketing platform.

"We forecast end-market growth to be volume-driven and supportive of further margin expansion. We project gross margin expansion of 120bp from FY 2024E to FY 2028E."

Share this article

Related Sharecast Articles

Sirius Real Estate ups dividend as profits jump 32%
(Sharecast News) - Profits at business and industrial parks developer Sirius Real Estate surged by nearly a third in the year ended 31 March, helping the company to increase dividends for the tenth straight year.
GSK to appeal Delaware ruling on jury trials in Zantac cancer cases
(Sharecast News) - Pharma giant GSK said it would be appealing against a US court decision allowing jury trials in cases brought by cancer sufferers claiming its heartburn drug caused their condition.
AstraZeneca's lung cancer treatment recommended for approval in EU
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.
China manufacturing PMI ticks up more than expected - Caixin
(Sharecast News) - Activity in China's manufacturing sector grew in May at the fastest rate in two years, according to data released on Monday.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.